Pharmac is transitioning to a trastuzumab biosimilar, Herzuma, from the currently funded brand, Herceptin. We are also widening access to locally advanced or metastatic HER2 positive gastric, gastro-oesophageal junction and oesophageal cancer. Learn more:
bit.ly/Notification2023-08-2…